Today's headlines suggest that a current drug trial has produced the first drug capable of halting Alzheimer's disease. However, scientific experts are urging caution in the way we react to these media stories.

The BBC's report is more cautious than some of the newspapers, including a quote from a leading dementia scientist that questioned the significance of the reports.

We asked our own Scientific Adviser, Seth Love, who is Professor of Neuropathology at the University of Bristol. He said, "I was disappointed rather than excited by the recent news. The overall outcome of the trial was negative, without significant cognitive benefit from this tau aggregation inhibitor. I am sceptical of reports of positive findings that depend on selective analysis of particular subsets of patients (in this case the 15% of patients who were not receiving cholinesterase inhibitors or any other drugs apart from LMTX). The study stands or falls according to whether or not it addresses the primary outcome measure for which the trial was designed. The subset analysis perhaps suggests that further study is needed."

BRACE Chief Executive Mark Poarch said, "It is clear that, while this is an interesting development, we do not yet know its import. Media excitement needs to be tempered by the realism of top scientists. Years' more research needs to be done before we can overcome Alzheimer's and the other forms dementia."